Interview With Timothy Ko

byPsychedelic SpotlightonMay 12, 2021

CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.

Episode Summary

In this episode of the Psychedelic Spotlight podcast, we spend some time with Timothy Ko who is the CEO of Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) a biotechnology company focused on developing psychedelic medicines to treat addiction.

In our conversation with Mr. Ko, we discuss how the company plans to utilize the psychedelic compound, DMT, to address the global addiction crisis, and how they are using genetics to develop more effective personalized treatment regimens for patients.

*To learn more about the company featured in this episode and the work they’re doing, visit their website: EntheonBiomedical.com

Interview with Joe Moore, Founder & CEO of Psychedelics Today

Podcasts

In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.

Interview With Steven Huang, DEI Consultant at MAPS and Numinus

Podcasts

Steven's consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space.

Interview With Laura Dawn

Podcasts

In today’s episode of the Psychedelic Spotlight podcast, we feature Laura Dawn- a microdosing mentor, visionary life coach, business consultant, author, international speaker, and host of the Psychedelic Leadership podcast.